Ivivi PEMF Technology Produces 80% Acceleration in Pain Relief in a Controlled Clinical Study Assessing Post-Surgical Pain
21 Mayo 2007 - 7:30AM
Business Wire
Ivivi Technologies, Inc. (AMEX:II), a leader in non-invasive,
electrotherapeutic technologies, today announced that preliminary
data from a randomized double-blind, placebo-controlled clinical
study entitled �Effect of Pulsed Electromagnetic Fields (�PEMF�) on
Post-Surgical Pain Reduction for Breast Augmentation� showed an 80%
acceleration in pain relief in patients treated with the active
technology as compared to patients treated with placebo units. The
study was conducted at Akademikliniken Hospital in Stockholm,
Sweden by Dr. Per Heden, an internationally-recognized plastic
surgeon and researcher, to quantify the effect of Ivivi�s
non-invasive PEMF technology on the reduction of pain in
post-operative breast augmentation patients. Patients in the study
were randomly assigned to either active or placebo treatment with
the wearable, lightweight, disposable Ivivi units, and assessed for
post-operative pain twice daily for several days after surgery. The
preliminary data was presented at the Akademikliniken�s
International Aesthetic Symposium that was held May 17-19, 2007 at
the Grand H�tel in Stockholm, Sweden. The presentation, entitled
�New Methods to Reduce Pain and Postoperative Discomfort� was
delivered by Dr. Patrick Maxwell, an internationally-recognized
plastic surgeon who currently serves as the chair of the Allergan
Academy�. Allergan, Inc. has an exclusive worldwide distribution
agreement to market, sell and distribute certain of Ivivi�s
products in the aesthetic and bariatric medical procedure markets.
�This study is the first to clinically confirm what plastic
surgeons have seen anecdotally, that Ivivi�s PEMF therapy is an
effective tool in reducing post-surgical pain,� commented Dr. Per
Heden, of the Department of Plastic Surgery at Akademikliniken
Hospital in Stockholm, and lead investigator on the study. �This
study reinforces our clinical data that shows the ability of our
technology to enhance post-surgical pain management. Since the
publication of the American Heart Association Guidelines urging
restricted use of non-steroidal anti-inflammatory drugs (NSAIDs),
the need for non-pharmacological pain control has become critical
for a large population of patients,� commented Andr� DiMino,
Co-CEO, Ivivi Technologies. About the Study In the study, pain was
measured twice daily beginning three to five hours after breast
augmentation surgery, and continuing for eight days. In the two
main arms of the study (15 patients each) one group of patients
wore active units that delivered PEMF therapy on both breasts for
30 minutes on a regular basis for the duration of the study. The
second had placebo units on each breast. For the data analysis, the
cumulative, daily pain measurements were plotted for each group,
and the slope of the group receiving treatment was compared to that
of the placebo group. Mean daily cumulative pain measurements in
patients receiving therapy decreased approximately 80% faster than
those in the placebo group (p
Equifin (AMEX:II)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Equifin (AMEX:II)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024
Real-Time news about Ivivi Technologies, Inc. (American Stock Exchange): 0 recent articles
Más de Ivivi Technologies, Inc. Artículos de Noticias